use Bluestar BioAdvisors est. net sales to calc a CF NPV XRx-008 Program Highlights – Independent Commercial Assessment
In support of ongoing pharmaceutical partnership discussions, XORTX initiated an independent commercial assessment of the XRx-008 program for ADPKD with Bluestar BioAdvisors. This evaluation included interviews with 30 Nephrologists and 10 “Payers” with Large national Plans that cover greater than 290 million lives. Outcome of this assessment suggests that the XRx-008 program for ADPKD worldwide peak net sales per year that may exceed $1B, with a total product life estimated to surpass 7 to 10 years
using a discount rate of 50%, the discounted cash flow value for a cash flow of $1 billion per year for 10 years is approximately $2,751,683,009
I have no idea how a partner might use this calculation to place a value on XORTX but this is one number based on a 50% discount rate using Bluestars numbers.
If there is anyone with industry experience to interpret this info for me, I invite you to please jump in. This seems like a HUGE opportunity!!??